Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics and Healthcare Resource Use (HRU) Among COVID-19 Patients With or Without Nirmatrelvir/Ritonavir (PAXLOVID™) Treatment in the Kingdom of Bahrain.

NCT06291831 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06291831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06291831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics and Healthcare Resource Use (HRU) Among COVID-19 Patients With or Without Nirmatrelvir/Ritonavir (PAXLOVID™) Treatment in the Kingdom of Bahrain.
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
March 13, 2024
Completion date
May 14, 2024
Enrollment
3,011 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19